Abstract
Tumor bone metastasis is one of the common complications of advanced tumor and one of the signs of poor prognosis. There are many targeted drugs for bone metastasis in the clinic, which play a very important role in the antitumor treatment and prevention of bone related events. Among them, zoledronic acid, a representative bisphosphonate drug, has been extensively studied. It has been found that zoledronic acid combined with other anti-tumor therapies can more effectively inhibit the occurrence of tumor and bone-related events. This article reviews the latest research on zoledronic acid combined with other anti-tumor methods to guide clinical use and provide research ideas. Key words: Bone neoplasms/SC/DT; Diphosphonates/TU; Antineoplastic combined chemotherapy protocols; Review
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
